Key result
To decrease gastrointestinal complications, acetylsalicylic acid should be taken at the lowest effective dose (75-81 mg daily), avoiding combinations with other anti-inflammatory drugs.
Why the study?
Gastrointestinal mucous coat lesions limit acetylsalicylic acid use in patients with atherothrombosis and strategies to improve safety are needed.
Does using the lowest effective dose of ASA and targeted preventive therapy reduce gastrointestinal complications in patients with atherothrombosis?
Does using the lowest effective dose of ASA and targeted preventive therapy reduce gastrointestinal complications in patients with atherothrombosis?
Using low-dose aspirin (75-81 mg) and targeted gastroprotection with PPIs in high-risk patients minimizes gastrointestinal complications in atherothrombosis management.
Supports low-dose acetylsalicylic acid monotherapy to limit GI risk; leaves open need for prospective validation before practice change.
Lesion of gastrointestinal mucous coat is the main factor limited acetylsalicylic acid (ASA) use in patients with atherothrombosis. Up to date the mostly comprehensible way to decrease gastrointestinal complications is taking ASA in the lowest effective dose, which is not higher than 75-81 mg daily. It is necessary if possible to avoid ASK usage in combination with other antiaggregants, anticoagulants, non-steroid and steroid anti-inflammatory drugs. Routine antiulcer therapy is not indicated for patients treated with ASA because there is a lack of clinical research data about efficacy of this approach. In high risk of dangerous gastrointestinal complications H. pylori eradication is recommended in combination with long term preventive therapy with gastric secretion inhibitors. Proton pump inhibitors are more preferred.
No takes yet. Share an insight, caveat, or question.
A. L. Komarov (2009) conducted a review in Atherothrombosis. Acetylsalicylic acid (ASA) was evaluated. To decrease gastrointestinal complications, acetylsalicylic acid should be taken at the lowest effective dose (75-81 mg daily), avoiding combinations with other anti-inflammatory drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: